Otsuka (OTCMKTS:OTSKY) Upgraded at UBS Group

UBS Group upgraded shares of Otsuka (OTCMKTS:OTSKY) to a hold rating in a research note published on Tuesday,Zacks.com reports.

A number of other equities analysts also recently commented on the stock. Morgan Stanley raised shares of Otsuka to an “overweight” rating in a research note on Friday, January 23rd. Zacks Research upgraded shares of Otsuka from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy”.

Otsuka Stock Up 1.0%

Shares of OTSKY opened at $29.97 on Tuesday. Otsuka has a 52-week low of $21.64 and a 52-week high of $30.64. The stock has a fifty day simple moving average of $29.04 and a two-hundred day simple moving average of $27.36.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.